Point-of-care test for rapid detection of invasive fungal diseases, enabling quick identification at the bedside or clinical laboratory. Facilitates early diagnosis and treatment decisions for immunocompromised patients at risk of invasive fungal infections.
Manufactured by
Dynamiker Biotechnology (Tianjin) Co., Ltd.
Tianjin, China
Dynamiker Biotechnology was founded in March 2014 and is located in Tianjin Eco-city. It is committed to the R D, production and global sales of innovative in vitro diagnostic products for invasive fungal diseases (IFD), new coronavirus diseases and other pathogenic microorganisms. We are gradually becoming the leading enterprise with competitive advantages in the joint detection and precision diagnosis industry segments. Dynamiker Biotechnology has established academician expert workstation, postdoctoral workstation, Tianjin key laboratory, Tianjin enterprise technology center. Dynamiker has presided over more than 20 national and Tianjin municipal scientific and technological major projects, obtained 67 nationally authorized patents and 62 medical device registration certificates. Dynamiker s products have been introduced into more than 2,000 key hospitals and Independent laboratories in China, and have been clinically applied in key hospitals in nearly 100 countries overseas. We have been participating in the establishment and development of the National Fungal Disease surveillance network, led by the National Health Commission, and set up the Research Center for Fungal Disease Diagnosis and Treatment . We have six core platforms, which are Ag/Ab preparation, molecular diagnostic, immunology, POCT, TAL (horseshoe crab) R D and Clinical Transformation. With the support of six core technology platforms, more and more new products are gradually introduced, like a series of fungal detection products covering a variety of fungal types, including Panfungal screening test, Invasive Aspergillosis, Invasive Candidiasis, Cryptococcosis, Mucomycosis, PJP, Fusarium, Talaromyces marneffei., a series of COVID-19 detection products developed during the fight against the epidemic, and bacterial drug resistance detection products developed in response to the call of the World Health Organization. All products are CE-IVD under ISO13485, More than 50 peer-reviewed papers and studies had proved the good quality of Dynamiker s kits. With the constatction of “One Belt, One Road”, Dynamiker Biotechnology fungal testing products have entered more than 500 key hospitals in more than 100 countries and regions in Asia, Europe, South America, Africa, and the Middle East by virtue of their strong competitive advantages. The hospital has completed the diagnosis of hundreds of millions of patients with fungal infection, contributing Chinese strength to the development of fungal detection medicine in the world. As the sole partner of GAFFI in China, Dynamiker Biotechonology actively cooperates with GAFFI to promote the establishment of international reference laboratories and industry standards. Adhere to the improvement of innovative technology and product quality, actively participate in industry-university-research and international project cooperation, and carry out strategic cooperation with Pfizer China to jointly promote the precise use of clinical antifungal drugs. In addition, Dynamiker innovative products have been included in the WHO product procurement list.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Lumigenex (Suzhou) Co., Ltd
China · 1 relevant product
Bio-Novum Sp.z o.o.
Poland · 1 relevant product
Access Bio, Inc.
United States · 1 relevant product
59 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →14 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 79 closest product alternatives
Lumigenex (Suzhou) Co., Ltd · China
Point-of-care testing device designed for rapid diagnosis of acute and chronic diseases. Enables immediate diagnostic results at the patient location, supporting timely clinical decision-making.
Bio-Novum Sp.z o.o. · Poland
Rapid diagnostic testing solution for point-of-care use in clinical settings. Enables quick identification of infections and diseases directly at the patient location.
Access Bio, Inc. · United States
RAPID POC TEST is a point-of-care diagnostic kit for rapid detection of infectious diseases, including COVID-19, with FDA Emergency Use Authorization. The test delivers serology and molecular results within 10 minutes to 83 minutes, enabling quick identification of current infection and past exposure. Designed for clinical settings and emergency response distribution across healthcare facilities and screening programs.
76 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products